Navigating the new normal: Debating the place of high-efficacy vs escalation treatment approaches in multiple sclerosis
18 November 2020
Job bag: MUL20-E063h | Date of preparation: November 2020
This meeting is organised and funded by Novartis Pharmaceuticals UK Limited
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Novartis via or online through the Patient Safety Information (PSI) tool at
If you have a question about a Novartis product, please contact Medical Information on 01276 698370 or by email at
To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.